DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients

Developmental Endothelial Locus-1 Serum Level and Its Relation With Thromboxane A2 and Platelet Count in Patients With Diabetic Nephropathy

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07749664

Acronym

DEL1-DN

Enrollment

Registered

2026-08-06

Start date

2026-09-01

Completion date

2027-01-01

Last updated

2026-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephropathy, Diabetic

Brief summary

Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease. Inflammation and platelet activation are believed to play a significant role in its pathogenesis and progression. Developmental endothelial locus-1 (DEL-1) is an anti-inflammatory protein that regulates leukocyte adhesion and endothelial function, while thromboxane A2 is a marker of platelet activation and contributes to vascular dysfunction. This study aims to evaluate serum levels of DEL-1 and thromboxane A2, and their relationship with platelet count in patients with diabetic nephropathy. Additionally, the study investigates the correlation between these biomarkers and disease severity. This observational cross-sectional study will be conducted on 80 participants, including patients with diabetic nephropathy and healthy controls, to explore the potential role of these biomarkers in disease progression and their possible use as diagnostic or prognostic indicators.

Interventions

OTHERNo intervention

No intervention is applied. This is an observational study involving clinical assessment and blood sample collection for laboratory analysis only.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Inclusion criteria

* Adult patients aged between 18 and 70 years. * Patients diagnosed with diabetic nephropathy based on clinical and laboratory findings. * Patients undergoing evaluation or follow-up for diabetic kidney disease. * Ability and willingness to provide informed consent.

Exclusion criteria

* \- Patients with known hepatic disease. * Patients with significant cardiovascular disease. * Patients with malignancy. * Patients who have undergone recent surgery. * Patients with known hematological disorders or hypercoagulable states. * Patients receiving medications that significantly affect platelet function.

Design outcomes

Primary

Measure	Time frame	Description
Serum level of Developmental Endothelial Locus-1 (DEL-1). Time Frame: Baseline	Baseline	Measurement of serum DEL-1 levels in patients with diabetic nephropathy compared with healthy controls.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 7, 2026